Alzheimer’s Disease/Dementia News

Changes in gene expression patterns in the brain associated with natural aging also were observed in the brains of those with severe COVID-19, prompting researchers to emphasize the need for neurological follow-up in recovered individuals.

Both moderate aerobic exercise and stretching and balance activities protected against cognitive decline in older adults with mild cognitive impairment, according to research at the Clinical Trials on Alzheimer’s Disease annual meeting.

Dementia prevalence dropped 3.7 percentage points in the U.S. from 2000 to 2016, according to a RAND Corporation study published in Proceedings of the National Academy of Sciences.

Lecanemab reduced amyloid markers and slowed cognitive decline in patients with early Alzheimer’s disease, although not without risk for adverse events, according to new data published in The New England Journal of Medicine.

Klotho protein levels in cerebrospinal fluid and plasma were associated with clinical stages of Alzheimer’s disease, cognitive decline, and amyloid and tau burden, independent of KL-VS heterozygosity status, according to research.

Researchers at Emory University are developing a visual tool to view how conditions such as Alzheimer's disease and autism spectrum disorder affect the brain in real-time, the university announced in a press release.

A practical risk score tool has been developed to help people identify their potential risk for dementia, researchers reported in JAMA Network Open.

A team of researchers at the University of Miami Miller School of Medicine have developed an online platform of metrics designed to assess a patient’s risk for developing Alzheimer’s disease and other neurological issues.

BrainCheck Inc. has received a $1.5 million grant award from the Small Business Innovation Research program, which it will use to fund a study of CARE, its digital cognitive care management platform, the company announced in a news release.

Gantenerumab, a treatment for mild cognitive impairment due to Alzheimer’s disease, did not meet the primary endpoint of slowing cognitive decline in a phase 3 clinical trial, Genentech announced in a released statement.